A detailed history of State Of Wisconsin Investment Board transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 40,730 shares of KYMR stock, worth $1.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
40,730
Previous 66,437 38.69%
Holding current value
$1.8 Million
Previous $1.98 Million 2.82%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.16 - $52.4 $775,323 - $1.35 Million
-25,707 Reduced 38.69%
40,730 $1.93 Million
Q2 2024

Aug 14, 2024

BUY
$29.85 - $39.42 $853,411 - $1.13 Million
28,590 Added 75.54%
66,437 $1.98 Million
Q1 2024

May 14, 2024

BUY
$22.9 - $43.57 $188,879 - $359,365
8,248 Added 27.87%
37,847 $1.52 Million
Q4 2023

Feb 12, 2024

SELL
$10.97 - $26.84 $98,993 - $242,204
-9,024 Reduced 23.36%
29,599 $753,000
Q3 2023

Nov 14, 2023

BUY
$13.9 - $23.88 $41,700 - $71,640
3,000 Added 8.42%
38,623 $536,000
Q2 2023

Aug 14, 2023

BUY
$22.4 - $34.92 $60,569 - $94,423
2,704 Added 8.21%
35,623 $818,000
Q1 2023

May 15, 2023

BUY
$24.84 - $38.75 $17,785 - $27,745
716 Added 2.22%
32,919 $975,000
Q4 2022

Feb 14, 2023

SELL
$19.57 - $30.92 $40,470 - $63,942
-2,068 Reduced 6.03%
32,203 $803,000
Q3 2022

Nov 14, 2022

BUY
$20.91 - $34.27 $56,749 - $93,008
2,714 Added 8.6%
34,271 $746,000
Q2 2022

Aug 15, 2022

SELL
$14.13 - $42.55 $204,079 - $614,549
-14,443 Reduced 31.4%
31,557 $621,000
Q1 2022

May 13, 2022

BUY
$35.3 - $64.68 $303,580 - $556,248
8,600 Added 22.99%
46,000 $1.95 Million
Q2 2021

Aug 12, 2021

BUY
$31.08 - $51.95 $739,704 - $1.24 Million
23,800 Added 175.0%
37,400 $1.81 Million
Q1 2021

May 17, 2021

BUY
$35.64 - $85.46 $484,704 - $1.16 Million
13,600 New
13,600 $528,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.41B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.